

South London and Maudsley NHS Foundation Trust: Q2 2016-2017 Performance in Delivering Research

| Id | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure Of Trial | Comments |
|-------|--|---|---|-----------------------------------|---|---|---|--|--|---|--|-----------------------------|------------|
| 13192 | 10/H1102/85 | 66298 | Protocol H8A-MC-LZAO Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid 3 Antibody in Patients with Alzheimer's Disease | Range Agreed | 1 | 5 | Not Available / Not Agreed | | 5 | 26/10/2015 | 5 | Recruitment Finished | 5 patients |